Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07057778
PHASE2
Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
Sponsor: Peking University People's Hospital
View on ClinicalTrials.gov
Summary
Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and Iguratimod in patients with steroid-resistant/relapsed ITP.
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-07-01
Completion Date
2027-07-01
Last Updated
2025-07-10
Healthy Volunteers
No
Conditions
Interventions
DRUG
Iguratimod
oral iguratimod at 25mg twice daily for 26 weeks
DRUG
low-dose rituximab
rituximab 100mg once weekly for 6 weeks
Locations (1)
Peking University Insititute of Hematology
Beijing, China